3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
1600
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1282
Lymphoma, Non-Hodgkin
1231
Leukemia, Lymphocytic, Chronic, B-Cell
1090
Lymphoma, Follicular
979
Lymphoma, Large B-Cell, Diffuse
853
Leukemia
790
Hodgkin Disease
777
Lymphoma, Mantle-Cell
675
Leukemia, Myeloid, Acute
540
Burkitt Lymphoma
507
Lymphoma, B-Cell, Marginal Zone
490
Multiple Myeloma
483
Myelodysplastic Syndromes
371
Lymphoma, Large-Cell, Immunoblastic
366
Recurrence
363
Lymphoma, T-Cell, Cutaneous
313
Neoplasms
309
Waldenstrom Macroglobulinemia
307
Lymphoma, Large-Cell, Anaplastic
254
Mycosis Fungoides
252
Lymphoma, B-Cell
231
Sezary Syndrome
229
Blast Crisis
210
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
208
Myeloproliferative Disorders
205
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
189
Neoplasms, Plasma Cell
188
Leukemia, Myeloid, Accelerated Phase
186
Leukemia, Myeloid, Chronic-Phase
179
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diffuse Large B-Cell Lymphoma Refractory
×
Lymphoid
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA